# Zeaxanthin Visual Performance Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/zeaxanthin-visual-performance-meta-analysis-evidence-review
Category: evidence-review
Summary: Zeaxanthin Visual Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass
Last reviewed: 2026-07-06
Reviewed by: Migaku Evidence Review
# Zeaxanthin Visual Performance Meta-analysis: What the Evidence Says

## Quick Answer

Zeaxanthin Visual Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials | systematic review | 1 | 2026-04-22 | 10.1155/joph/2155378 |
| Beneficial Effects of Natural Bioactive Compounds on Eye Health: A Narrative Review | preclinical study | 4 | 2026-05-20 | 10.3390/ijms27104592 |

## What The Sources Report

- However, these approaches require repeated invasive injections and are associated with considerable economic burden and procedural risks. [Wang Wei-Xiang (2026); evidence level 1]
- Experimental and clinical studies have suggested that increased macular pigment levels may support visual performance and potentially attenuate AMD progression. [Wang Wei-Xiang (2026); evidence level 1]
- Major vision-threatening conditions such as glaucoma, cataracts, age-related macular degeneration (AMD), diabetic retinopathy (DR), uveitis, retinal detachment, etc., contribute significantly to functional disability and reduced quality of life. [De Silva Sandun (2026); evidence level 4]
- Oxidative stress, chronic inflammation, mitochondrial dysfunction, dysregulated angiogenesis and metabolic imbalance are highly associated with the molecular-level pathogenesis of these ocular diseases. [De Silva Sandun (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For zeaxanthin visual performance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Wang Wei-Xiang (2026). From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. DOI: 10.1155/joph/2155378. PMCID: PMC13101954. PMID: 42028334. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13101954/
- De Silva Sandun (2026). Beneficial Effects of Natural Bioactive Compounds on Eye Health: A Narrative Review. DOI: 10.3390/ijms27104592. PMCID: PMC13207216. PMID: 42196569. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13207216/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.